218 related articles for article (PubMed ID: 22610342)
1. Histology-specific therapy for advanced soft tissue sarcoma and benign connective tissue tumors.
Silk AW; Schuetze SM
Curr Treat Options Oncol; 2012 Sep; 13(3):285-98. PubMed ID: 22610342
[TBL] [Abstract][Full Text] [Related]
2. Overview of « druggable » alterations by histological subtypes of sarcomas and connective tissue intermediate malignancies.
Penel N; Lebellec L; Blay JY; Robin YM
Crit Rev Oncol Hematol; 2020 Jun; 150():102960. PubMed ID: 32320927
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic strategies for soft tissue sarcomas.
von Mehren M
Curr Treat Options Oncol; 2003 Dec; 4(6):441-51. PubMed ID: 14585225
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
Chawla SP; Staddon AP; Baker LH; Schuetze SM; Tolcher AW; D'Amato GZ; Blay JY; Mita MM; Sankhala KK; Berk L; Rivera VM; Clackson T; Loewy JW; Haluska FG; Demetri GD
J Clin Oncol; 2012 Jan; 30(1):78-84. PubMed ID: 22067397
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic pipeline for soft-tissue sarcoma.
Cassier PA; Labidi-Galy SI; Heudel P; Dutour A; Méeus P; Chelghoum M; Alberti L; Ray-Coquard I; Blay JY
Expert Opin Pharmacother; 2011 Nov; 12(16):2479-91. PubMed ID: 21913865
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.
Chmielowski B; Federman N; Tap WD
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1217-28. PubMed ID: 23098121
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
García Del Muro X; Maurel J; Martínez Trufero J; Lavernia J; López Pousa A; de Las Peñas R; Cubedo R; Berros JP; Casado Herráez A; de Juan A; Martín Broto J
Invest New Drugs; 2018 Jun; 36(3):468-475. PubMed ID: 29527631
[TBL] [Abstract][Full Text] [Related]
8. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
Xie L; Guo W; Wang Y; Yan T; Ji T; Xu J
BMC Cancer; 2018 Apr; 18(1):396. PubMed ID: 29625604
[TBL] [Abstract][Full Text] [Related]
9. Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.
Mita MM; Gong J; Chawla SP
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):465-82. PubMed ID: 23971829
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapies for adult soft tissue sarcoma.
Radaelli S; Stacchiotti S; Casali PG; Gronchi A
Expert Rev Anticancer Ther; 2014 Jun; 14(6):689-704. PubMed ID: 24555529
[TBL] [Abstract][Full Text] [Related]
11. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Hartmann JT
Anticancer Drugs; 2007 Mar; 18(3):245-54. PubMed ID: 17264755
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Dembla V; Groisberg R; Hess K; Fu S; Wheler J; Hong DS; Janku F; Zinner R; Piha-Paul SA; Ravi V; Benjamin RS; Patel S; Somaiah N; Herzog CE; Karp DD; Roszik J; Meric-Bernstam F; Subbiah V
Sci Rep; 2017 Nov; 7(1):15963. PubMed ID: 29162825
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 clinical trials for sarcomas: the cutting edge.
Subbiah V; Kurzrock R
Curr Opin Oncol; 2011 Jul; 23(4):352-60. PubMed ID: 21519259
[TBL] [Abstract][Full Text] [Related]
14. Treating soft tissue sarcomas with adjuvant chemotherapy.
Patrikidou A; Domont J; Cioffi A; Le Cesne A
Curr Treat Options Oncol; 2011 Mar; 12(1):21-31. PubMed ID: 21384115
[TBL] [Abstract][Full Text] [Related]
15. Advances and controversies in the management of soft tissue sarcomas.
Demetri GD; Blay JY; Casali PG
Future Oncol; 2017 Jan; 13(1s):3-11. PubMed ID: 27918199
[TBL] [Abstract][Full Text] [Related]
16. New Drug Approvals for Sarcoma in the Last 5 Years.
Thirasastr P; Brahmi M; Dufresne A; Somaiah N; Blay JY
Surg Oncol Clin N Am; 2022 Jul; 31(3):361-380. PubMed ID: 35715139
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Tawbi HA; Burgess M; Bolejack V; Van Tine BA; Schuetze SM; Hu J; D'Angelo S; Attia S; Riedel RF; Priebat DA; Movva S; Davis LE; Okuno SH; Reed DR; Crowley J; Butterfield LH; Salazar R; Rodriguez-Canales J; Lazar AJ; Wistuba II; Baker LH; Maki RG; Reinke D; Patel S
Lancet Oncol; 2017 Nov; 18(11):1493-1501. PubMed ID: 28988646
[TBL] [Abstract][Full Text] [Related]
18. The Current Landscape of Early Drug Development for Patients With Sarcoma.
Wilky BA; Jones RL; Keedy VL
Am Soc Clin Oncol Educ Book; 2017; 37():807-810. PubMed ID: 28561654
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma.
Hartmann JT; Patel S
Drugs; 2005; 65(2):167-78. PubMed ID: 15631540
[TBL] [Abstract][Full Text] [Related]
20. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
Kopp HG; Patel S; Brücher B; Hartmann JT
Am J Clin Dermatol; 2008; 9(4):207-17. PubMed ID: 18572972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]